This application represents unprecedented cooperation among excellent institutions, major sarcoma dedicated non-profit organizations, and the NCI intramural Program. This SPORE originates from SARC, a non-for-profit consortium that facilitates the conduct of research among national centers of excellence in sarcoma. The main goals of the SARC Sarcoma SPORE are the translation of biological and technological advances into improvements in prevention, diagnostics, predictors of outcome, and - particularly - advances in the treatment of sarcoma. The SARC Sarcoma SPORE is anchored by multiple researchers from SARC, Harvard, MD Anderson Cancer Center, and the NCI intramural program, but also includes key individual researchers from Stanford University, Columbia University and The University of Michigan. The researchers represent medical and pediatric oncology and the projects explore both soft tissue and bone sarcomas. Four major projects are proposed: 1) HDACi-based therapeutic strategies for the treatment of genetically complex STS;2) Identification of therapeutic windows for NFI-related malignant peripheral nerve sheath tumor;3) Investigation of G-protein coupled receptors as biomarkers of aggressive disease and novel therapeutic targets in Ewing sarcoma;and 4) Development of quantitative imaging biomarkers for assessing therapeutic response to sarcoma therapy using advanced approaches in PET and MRl. These projects are integrated and supported by 4 cores: 1) Administration, Evaluation and Planning;2) Tissue and Pathology;3) Clinical Trials;and 4) Biostatistics. The SPORE application outlines a Developmental Research Program that includes a plan for selection of new projects as well as 14 proposed developmental pilot projects. We also include a Career Developmental Program that outlines a mechanism for the identification and support of talented young investigators in translational or clinical sarcoma research. The projects, cores and programs are highly integrated and are poised to take maximum advantage of the SPORE mechanism to achieve translational goals. This SPORE joins state-of-the-art research projects with the multi-institution, collaborative strength of SARC and commitments from leading institutions to produce translational advances.

Public Health Relevance

Currently, there are limited programs that have the capability to provide the infrastructure for collaboration on translational research for sarcoma. Because sarcoma is a relatively uncommon disease, this SARC Sarcoma SPORE will provide the infrastructure for translational research to develop and test the feasibility of cancer relevant interventions in humans and/or determine the biological basis for observations made in individuals with sarcoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA168512-02
Application #
8551649
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Program Officer
Ujhazy, Peter
Project Start
2012-09-26
Project End
2017-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
2
Fiscal Year
2013
Total Cost
$2,150,500
Indirect Cost
$94,871
Name
Sarc
Department
Type
DUNS #
186146911
City
Ann Arbor
State
MI
Country
United States
Zip Code
48106
Nakayama, Robert; Zhang, Yi-Xiang; Czaplinski, Jeffrey T et al. (2016) Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. Oncotarget 7:16581-92
Goldstein, Seth D; Trucco, Matteo; Bautista Guzman, Wendy et al. (2016) A monoclonal antibody against the Wnt signaling inhibitor dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model. Oncotarget 7:21114-23
Schaefer, Inga-Marie; Fletcher, Christopher Dm; Hornick, Jason L (2016) Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod Pathol 29:4-13
Mariño-Enríquez, Adrián; Bovée, Judith V M G (2016) Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma. Surg Pathol Clin 9:457-73
Tang, Qin; Moore, John C; Ignatius, Myron S et al. (2016) Imaging tumour cell heterogeneity following cell transplantation into optically clear immune-deficient zebrafish. Nat Commun 7:10358
Bobowski, Nina P; Baker, Laurence H (2016) The University of Michigan Sarcoma Survivorship Clinic: Preventing, Diagnosing, and Treating Chronic Illness for Improved Survival and Long-Term Health. J Adolesc Young Adult Oncol 5:211-4
Koehler, K; Liebner, D; Chen, J L (2016) TP53 mutational status is predictive of pazopanib response in advanced sarcomas. Ann Oncol 27:539-43
Bid, Hemant K; Phelps, Doris A; Xaio, Linlin et al. (2016) The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma. Mol Cancer Ther 15:1018-28
Simon, Priscilla S; Bardhan, Kankana; Chen, May R et al. (2016) NF-κB functions as a molecular link between tumor cells and Th1/Tc1 T cells in the tumor microenvironment to exert radiation-mediated tumor suppression. Oncotarget 7:23395-415
De Rienzo, Assunta; Archer, Michael A; Yeap, Beow Y et al. (2016) Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma. Cancer Res 76:319-28

Showing the most recent 10 out of 86 publications